胸部放疗中免疫细胞估算辐射剂量的预后意义:一项荟萃分析
结果显示较高的免疫细胞估算辐射剂量与较差的总生存、无进展生存、无病生存、局部区域无进展生存和远处无转移生存均显著相关。作者认为免疫保护性放疗策略可能改善预后,需进一步研究。
要点
- 较高的免疫细胞估算辐射剂量与肺癌和食管癌放疗患者较差的总生存显著相关(HR=1.228,95%CI 1.135-1.329,p<0.001)。
- 该剂量亦与较差的无进展生存、无病生存、局部区域无进展生存和远处无转移生存显著相关。
- 亚组分析在肿瘤类型、地区、年龄、样本量和截断值方面结果一致,提示免疫保护性放疗策略可能改善预后。
核心结论
- 较高的免疫细胞估算辐射剂量与肺癌和食管癌放疗患者的不良生存结局相关。
- 免疫保护性放疗策略可能改善预后,值得进一步研究。
研究设计与样本
- 系统检索PubMed、EMBASE和Cochrane Library截至2025年4月,遵循PRISMA指南。
- 采用随机效应模型计算汇总风险比(HR)及95%置信区间(CI)。
主要发现
- 较高的免疫细胞估算辐射剂量与较差的总生存显著相关(HR=1.228;95%CI 1.135-1.329;p<0.001)。
- 较高的免疫细胞估算辐射剂量与较差的无进展生存显著相关(HR=1.265;95%CI 1.134-1.412;p<0.001)。
- 无病生存(HR=1.227;95%CI 1.009-1.492)、局部区域无进展生存(HR=1.091;95%CI 1.042-1.141)和远处无转移生存(HR=1.172;95%CI 1.066-1.290)也观察到类似关联。
- 亚组分析在肿瘤类型、地理区域、年龄组、样本量和免疫细胞估算辐射剂量截断值方面结果一致。
- 漏斗图不对称和统计检验提示潜在发表偏倚,但剪补法分析证实结果稳健,敏感性分析支持汇总估计的稳定性。
关键数值与推荐
- 较高的免疫细胞估算辐射剂量与较差的总生存相关:HR=1.228;95%CI 1.135-1.329;p<0.001。
- 较高的免疫细胞估算辐射剂量与较差的无进展生存相关:HR=1.265;95%CI 1.134-1.412;p<0.001。
- 无病生存:HR=1.227;95%CI 1.009-1.492。
- 局部区域无进展生存:HR=1.091;95%CI 1.042-1.141。
- 远处无转移生存:HR=1.172;95%CI 1.066-1.290。
临床怎么用
- 在肺癌和食管癌胸部放疗计划评估中,可关注免疫细胞估算辐射剂量这一指标。
- 考虑采用免疫保护性放疗策略以可能改善患者预后。
局限性
- 漏斗图不对称和统计检验提示潜在发表偏倚。
- 免疫细胞估算辐射剂量的截断值在不同研究间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Emerging evidence suggests that excessive radiation dose to immune cells may impair host immunity and negatively affect cancer prognosis. However, the prognostic impact of the estimated radiation dose to immune cells across different cancer types and treatment modalities remains inconclusive. This meta-analysis aimed to systematically evaluate the association between estimated radiation dose to immune cells and survival outcomes in patients with lung and esophageal cancers undergoing radiotherapy. MATERIALS AND METHODS: We systematically searched PubMed, EMBASE, and Cochrane Library up to April 2025 following PRISMA guidelines. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), locoregional progression-free survival (LPFS), and distant metastasis-free survival (DMFS). RESULTS: Sixteen studies comprising 4511 patients were included, with 1073 patients diagnosed with esophageal cancer and 3438 with lung cancer. The pooled analysis demonstrated that higher estimated radiation dose to immune cells was significantly associated with inferior OS (HR = 1.228; 95 % CI, 1.135-1.329; p < 0.001) and PFS (HR = 1.265; 95 % CI, 1.134-1.412; p < 0.001). Similar associations were observed for DFS (HR = 1.227; 95 % CI, 1.009-1.492), LPFS (HR = 1.091; 95 % CI, 1.042-1.141), and DMFS (HR = 1.172; 95 % CI, 1.066-1.290). Subgroup analyses revealed consistent findings across tumor types, geographic regions, age groups, sample sizes, and the estimated radiation dose to immune cells cutoff values. Funnel plot asymmetry and statistical tests suggested potential publication bias; however, trim-and-fill analyses confirmed the robustness of the results. Sensitivity analyses further supported the stability of pooled estimates. CONCLUSIONS: Higher estimated radiation dose to immune cells is linked to adverse survival outcomes. Immune-sparing radiotherapy strategies may improve prognosis and warrant further investigation.
引用
- Luan CW, Tsai YT, Chen KY, et al. Prognostic significance of estimated radiation dose to immune cells in cancer patients undergoing thoracic irradiation: A meta-analysis. Radiother Oncol. 2025. PMID: 40921330. doi:10.1016/j.radonc.2025.111123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。